Gossamer Bio submits FDA NDA for seralutinib in pulmonary arterial hypertension

• Gossamer Bio submitted a New Drug Application to the FDA in September 2026 for seralutinib to treat pulmonary arterial hypertension.
• The filing is backed by the Phase 3 PROSERA study, with confirmatory evidence from the Phase 2 TORREY study.
• The FDA is expected to decide on acceptance for filing later this year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gossamer Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260923338443) on September 23, 2026, and is solely responsible for the information contained therein.